According to Zacks, “Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States. “
A number of other equities research analysts have also recently issued reports on the stock. SunTrust Banks dropped their target price on shares of Eloxx Pharmaceuticals to $10.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Janney Montgomery Scott started coverage on shares of Eloxx Pharmaceuticals in a research report on Friday, September 6th. They set a “buy” rating and a $14.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $12.80.
Shares of Eloxx Pharmaceuticals stock traded down $0.09 during mid-day trading on Friday, reaching $6.38. 38,913 shares of the stock were exchanged, compared to its average volume of 55,763. The firm has a 50-day simple moving average of $6.68 and a 200 day simple moving average of $9.76. Eloxx Pharmaceuticals has a fifty-two week low of $5.14 and a fifty-two week high of $17.50.
Eloxx Pharmaceuticals (OTCMKTS:ELOX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03).
In related news, major shareholder Pontifax Management 4 G.P. (20 acquired 200,000 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were purchased at an average price of $9.00 per share, with a total value of $1,800,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 44.03% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA bought a new stake in Eloxx Pharmaceuticals during the 1st quarter worth about $55,000. Bank of America Corp DE grew its holdings in Eloxx Pharmaceuticals by 226.0% during the 4th quarter. Bank of America Corp DE now owns 14,209 shares of the company’s stock worth $171,000 after acquiring an additional 9,851 shares during the last quarter. Advisor Group Inc. grew its holdings in Eloxx Pharmaceuticals by 458.0% during the 2nd quarter. Advisor Group Inc. now owns 12,359 shares of the company’s stock worth $123,000 after acquiring an additional 10,144 shares during the last quarter. Northern Trust Corp grew its holdings in Eloxx Pharmaceuticals by 4.6% during the 2nd quarter. Northern Trust Corp now owns 300,197 shares of the company’s stock worth $2,993,000 after acquiring an additional 13,116 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Eloxx Pharmaceuticals by 12.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 129,169 shares of the company’s stock worth $1,288,000 after acquiring an additional 14,118 shares during the last quarter.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.